Acute Migraine
Migraine is a common and debilitating brain disorder that remains poorly treated for many patients. There are approximately 650 million headaches treated each year* and approximately 1.2 million emergency room visits due to migraines.
Approximately 33.8 million people suffer from either episodic or chronic migraine. Of those, an estimated 20% to 30% either do not respond to or cannot tolerate the market-leading triptan drug class.
The total migraine drug market is approximately $3.45 billion and is projected to continue growing at a rate of 12% per year through 2027.1
*Chronic migraine defined as >15 attacks per month.
- Decision Resources, Pharmacor migraine market landscape and forecast 2018.
- Chu Sin Chung P, Kieffer BL. Delta opioid receptors in brain function and diseases. Pharmacol Ther. 2013 Oct;140(1):112-20.
- Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E, Befort K, Kieffer BL. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Behav Brain Res. 2015 Feb 1;278:429-34.
- Fossler MJ, Schmith V, Greene SA, et al. CNS Drugs. 2020;34(8):853-865.